TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in pharmacokinetic parameter Cmin of dolutegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in fat mass in pounds via bioimpedance analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in fat mass in pounds via ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in muscle mass in pounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to start the first mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative recovery index results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total mobilization time in the first 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of alignment of lower anterior teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of women with vaginal dysbiosis after 3 months of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of women with vaginal dysbiosis after 6 months of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants recruited to I-ER GD
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants recruited to I-ER SUPPORT
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Grade 2 and higher ILD including radiation pneumonitis
Endpoint domain: Adverse events/effects
Primary endpoint: Change in shade matching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of vital pulp therapy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Regional splanchnic blood flow increase in response to meal test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in blood levels of gastrointestinal hormones and markers of metabolism following meal test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement of the patient's clinical condition based on the WHO ordinal outcomes score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Blood Parameters (D-dimer)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Blood Parameters (C-reactive protein)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in VAS pain score (only for varicose vein panelist)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Number of Participants Reporting One or More Treatment Emergent Serious Adverse events (TESAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in the Alberta Infant Motor Scale (AIMS) at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in the Early Motor Development Questionnaire (EMQ) at 8 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of rehospitalisation
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Intrauterine pathology detection rate with Hydrosonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Intrauterine pathology detection rate with Visual Saline Infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Pathogen detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximal oxygen uptake (VO2max; ml/min/kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary arterial systolic pressure (PASP; mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dyspnoea Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Functional recovery of upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bystander Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intention to Help Scale-Short Version
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bystander Behavior Scale (For Friends)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Cost-effectiveness of the CATSystem Intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: modified McKay's criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: finger tapping speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: forearm speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: UPDRS-III rigidity subscore
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain with general movement involving the chest and upper body
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived stress reactivity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Disease activity in psoriatic arthritis (DAPSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Psoriatic Arthritis Quality of Life (PsAQoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ischemia time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Recurrent VTE risk
Endpoint domain: Mortality/survival
Primary endpoint: Major bleeding or clinically-relevant non-major bleeding-related hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory blood tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Knowledge level on end-of-life care nursing
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Attitude score toward the care of the patient during the death process
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positive-negative mood level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Glycosylated Hemoglobin Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Perioperative Risk of Myocardial Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Fecal characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Addiction Severity Index for Methamphetamine Use Disorder
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fingertip length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peak FENa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in distal sodium reabsorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Safety and tolerability of FL115
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of Urinary Incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: T helper 1 cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T helper 2 cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T helper 17 cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Urinary Biomarkers NGAL and KIM-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Participants With Serological Response Against SARS-CoV-2 Original Strain 14 Days After Booster Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Original Strain 14 Days After Booster Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Serological Response Against SARS-CoV-2 Delta Variant 14 Days After Booster Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Intraoperative remifentanil consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Postoperative tramadol consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: airway lumen opening rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: crust formation degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: granuloma formation degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Success at two weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Success at one year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic Success at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic Success at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Gross Motor Function Measure-88 at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Trunk Control Measurement Scale at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Pediatric Evaluation of Disability Inventory at 8 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Xerostomia symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Curative resection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: lipid profile change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: glomerular function range change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: creatinine change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Failure/rejection rate of samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Grade 4 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Grade 3 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of patients achieving >50% urine pH above 7.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: function disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: core muscles endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Granulation coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of sections performed under general anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of in-surgery conversion from regional to general anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Portal venous pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic artery blood flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fracture reduction quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: mean of pain felt during the whole IVAD procedure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean of anxiety felt during the whole IVAD procedure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity and specificity of medical team
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in clinical examination on eyes and peri-ocular skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in subjective evaluation of ocular and cutaneous signs by subjects
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Local tolerance assessed by Investigator
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of ischemic stroke or death
Endpoint domain: Mortality/survival
Primary endpoint: Accuracy of implant position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in cigarette-related toxicant exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antitumor efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in symptomatic remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in intestinal inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of Functionality
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient Satisfaction of different types of dermatologic care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in Intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change from baseline in pupillary diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Proportion of subjects with sUA levels <6.0 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Multiple System Atrophy Quality of Life (MSA-QoL) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Barthel Index for Activity of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of delirium within 4 days after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Progression-free survival after surgery
Endpoint domain: Mortality/survival
Primary endpoint: Serum prolidase level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Time Zero to the Last Timepoint with Measurable Concentration (AUC[0-tlast])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of Coronary Heart Disease (CHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeatability of fTT measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of tubal pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Acquisitions of pre-specified MDROs
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase 2 dose (RP2D) of ZX-4081
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of ZX-4081
Endpoint domain: Adverse events/effects
Primary endpoint: 3D mandibular condylar position changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signs of temporomandibular disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of surgical re-interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from Baseline in Neck disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Biodex isokinetic dynamometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Montreal cognitive assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Fugl Myer upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Removal of middle molecular weight uremic toxins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Onset time of femoral nerve block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: aMMP-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychophysiological reactivity to script-driven imagery (SDI-PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician-Administered PTSD scale for DSM-5 (CAPS-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in McGill Pain Questionnaire (SF-MPQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score using the Numeric Rating Scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety score using the Generalized Anxiety Disorder-7 (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical manageability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of fetuses delivered for non-reassuring fetal status
Endpoint domain: Mortality/survival
Primary endpoint: Change in melatonin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Diagnostic Yield of rapid genome sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate clinical utility of rapid genome sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAR BCMA related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Walking Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Listening Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall Preference
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Disordered eating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Community reintegration scores
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Caregiver burden scores
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change from baseline in Scale for the assessment and rating of ataxia (SARA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mortality rate among COPD patients
Endpoint domain: Mortality/survival
Primary endpoint: Readiness for Change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Self-Efficacy for Drug Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Doppler US measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major adverse cardiovascular and limb events (MACE or MALE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average three-dimensional volumetric increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Home NIV Compliance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: HEART score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in LLSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-cause post-hospitalization mortality
Endpoint domain: Mortality/survival
Primary endpoint: Chronic pain symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of 18F-PSMA-11
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiological parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasticity of spinal neuronal networks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasticity of corticospinal networks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Return-to-work Self-efficacy Scale (RTW-SE)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Complete colonoscopy defined by caecum intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of NG
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Leukocyte values at a week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Gestures decoding improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elicitation of somatic sensations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of days with menstrual bleeding changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HbA1c concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dose schedule limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Percent arachidonic acid-induced platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes